Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Sabashini K Ramchand und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia. Hauptthemen laut MEDLINE: Denosumab, Breast Neoplasms, Premenopause, Estradiol. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of estradiol suppression and has been reported to have effects on body composition and metabolic parameters in preclinical and observational studies, but evidence from double-blind randomized controlled trials is limited.
Objective
To assess the effect of denosumab on body composition and metabolic parameters.
Methods
In a prespecified secondary analysis of a 12-month randomized, double-blind, placebo-controlled trial, 68 premenopausal women with breast cancer initiating ovarian function suppression and aromatase inhibition were randomized to denosumab 60-mg or placebo administered at baseline and 6 months. Outcome measures were total and regional fat and lean mass (DXA), body mass index (BMI), waist and hip circumference, fasting glucose, HOMA-IR, and lipid profile. Using a mixed model, between-group mean adjusted differences over time are reported.
Results
Over 12 months, relative to placebo, android and gynoid fat mass decreased in the denosumab group (−266 g [95% CI −453 to −79], P = .02, and −452 g [−783 to −122], P = .03, respectively). Total fat mass and waist circumference were lower in the denosumab group but not significantly (−1792 g [−3346 to −240], P = .08 and (− 3.77 cm [−6.76 to −0.79], P = .06, respectively). No significant treatment effects were detected in lean mass, BMI, hip circumference, fasting glucose, HOMA-IR, or lipid profile.
Conclusion
In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, MA 02114, USA.
- Olivia Newton-John Cancer & Wellness Centre, Austin Health, Victoria 3084, Australia.
- Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3052, Australia.
- Department of Endocrinology, Austin Health, Victoria 3084, Australia.
ORCID-Profile: Sabashini K Ramchand, Mathis Grossmann
Zitieren
APA
Ramchand, S. K., Hoermann, R., White, S., Yeo, B., Francis, P. A., Xu, C. L. H., Zajac, J. D., Seeman, E., & Grossmann, M. (2024). Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae003
Vancouver
Ramchand SK, Hoermann R, White S, Yeo B, Francis PA, Xu CLH, et al. Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae003
BibTeX
@article{Ramchand2024,
author = {Ramchand, Sabashini K and Hoermann, Rudolf and White, Shane and Yeo, Belinda and Francis, Prudence A and Xu, Cecilia L H and Zajac, Jeffrey D and Seeman, Ego and Grossmann, Mathis},
title = {Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae003}
}
EUVIMED